Anemia may be common in the elderly patient, but it should not be accepted as normal aging. The scientific evidence suggests that consequences of untreated geriatric anemia are significant. Anemia leads to poorer quality of life and increased morbidity and mortality. Even mild anemia is more significant than traditionally thought by clinicians and is associated with increased hospitalizations and mortality. This course will review physical assessment skills, laboratory findings, diagnosis, and initiation of treatment and follow-up plan.
This course is designed for physicians, physician assistants, nurses, and other healthcare professionals involved in the care of elderly patients.
NetCE is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. NetCE is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. NetCE is approved by the California Nursing Home Administrator Program as a provider of continuing education. Provider number 1622. NetCE is approved to offer continuing education through the Florida Board of Nursing Home Administrators, Provider #50-2405. NetCE is accredited by the International Association for Continuing Education and Training (IACET). NetCE complies with the ANSI/IACET Standard, which is recognized internationally as a standard of excellence in instructional practices. As a result of this accreditation, NetCE is authorized to issue the IACET CEU. NetCE is approved as a provider of online continuing education for certified nursing assistants through the California Department of Public Health Licensing and Certification Division. Nurse Aide Certification (NAC) Provider #7005. This program has been pre-approved by The Commission for Case Manager Certification to provide continuing education credit to CCM® board certified case managers. The course is approved for 5 CE contact hour(s). Activity code: H00021045. Approval Number: 160001837. To claim these CEs, log into your CE Center account at www.ccmcertification.org.
NetCE designates this enduring material for a maximum of 5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. NetCE designates this continuing education activity for 5 ANCC contact hour(s). NetCE designates this continuing education activity for 2 pharmacotherapeutic/pharmacology contact hour(s). NetCE designates this continuing education activity for 6 hours for Alabama nurses. Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Completion of this course constitutes permission to share the completion data with ACCME. This home study course is approved by the Florida Board of Nursing Home Administrators for 5 credit hour(s). This course is approved by the California Nursing Home Administrator Program for 5 hour(s) of continuing education credit - NHAP#1622005-5394/P. California NHAs may only obtain a maximum of 10 hours per course. AACN Synergy CERP Category A. NetCE is authorized by IACET to offer 0.5 CEU(s) for this program.
In addition to states that accept ANCC, NetCE is approved as a provider of continuing education in nursing by: Alabama, Provider #ABNP0353, (valid through December 12, 2017); California, BRN Provider #CEP9784; California, LVN Provider #V10662; California, PT Provider #V10842; Florida, Provider #50-2405; Iowa, Provider #295; Kentucky, Provider #7-0054 through 12/31/2017.
This activity is designed to comply with the requirements of California Assembly Bill 1195, Cultural and Linguistic Competency.
The purpose of this course is to provide healthcare providers with the knowledge and tools necessary to identify anemia early and respond appropriately. Better health outcomes for the geriatric population will result from an increase in evidence-based clinical practices.
Upon completion of this course, you should be able to:
- Define anemia and its impact on the geriatric population.
- Describe the pathophysiology of anemia of chronic inflammation.
- Outline the role of nutrient deficiencies in the development of anemia.
- Compare and contrast other possible causes of anemia in the elderly.
- Discuss standards for the assessment of elders with anemia.
- Develop a treatment plan for geriatric patients with anemia.
Susan Waterbury, MSN, FNP-BC, ACHPN, entered the medical field as an RN in 1990. She continued her education, achieving a Master’s Degree from the University of Central Florida in 1999. She has worked as a Family and Geriatric Nurse Practitioner since 2000, in family practice, geriatrics, hospice, and palliative care. She achieved board certification as a Family Nurse Practitioner in 2000 and as an Advanced Certified Hospice and Palliative Care Nurse in 2006. She holds nurse practitioner licenses in Florida, Virginia, and Maryland.
In addition to her clinical positions, Ms. Waterbury continues to play an active role in educating and mentoring nurses and other healthcare professionals. She is a faculty member of University of Phoenix, focusing on nursing leadership. She has developed and presented many educational programs for a variety of healthcare organizations and community groups.
Contributing faculty, Susan Waterbury, MSN, FNP-BC, ACHPN, has disclosed no relevant financial relationship with any product manufacturer or service provider mentioned.
John M. Leonard, MD
Jane C. Norman, RN, MSN, CNE, PhD
The division planners have disclosed no relevant financial relationship with any product manufacturer or service provider mentioned.
The purpose of NetCE is to provide challenging curricula to assist healthcare professionals to raise their levels of expertise while fulfilling their continuing education requirements, thereby improving the quality of healthcare.
Our contributing faculty members have taken care to ensure that the information and recommendations are accurate and compatible with the standards generally accepted at the time of publication. The publisher disclaims any liability, loss or damage incurred as a consequence, directly or indirectly, of the use and application of any of the contents. Participants are cautioned about the potential risk of using limited knowledge when integrating new techniques into practice.
It is the policy of NetCE not to accept commercial support. Furthermore, commercial interests are prohibited from distributing or providing access to this activity to learners.
Supported browsers for Windows include Microsoft Internet Explorer 9.0 and up, Mozilla Firefox 3.0 and up, Opera 9.0 and up, and Google Chrome. Supported browsers for Macintosh include Safari, Mozilla Firefox 3.0 and up, Opera 9.0 and up, and Google Chrome. Other operating systems and browsers that include complete implementations of ECMAScript edition 3 and CSS 2.0 may work, but are not supported.
#99081: Anemia in the Elderly
The incidence of anemia increases with age, and anemia can be common in the elderly patient. However, it should not be accepted as a part of normal aging. Growing scientific evidence suggests that the consequences of untreated geriatric anemia are significant, with poor outcomes associated with anemic elders and increased morbidity and mortality over 5 years [1,2]. Anemia can also have a significant effect on healthcare expenditures and on the growing burden on the healthcare system. As the geriatric population increases, experts predict that anemia will become a significant issue [3,4]. Due to the projected increase in the elderly population, clinicians should become knowledgeable in diseases common in geriatrics. This course will provide healthcare providers the knowledge and tools necessary to identify anemia early and respond appropriately. Health outcomes for the geriatric population should improve if evidence-based clinical practices are incorporated into their care.
As noted, the risk of developing anemia increases with age. The prevalence of anemia is higher in elderly men than women, with the highest incidence occurring in men older than 85 years of age [5,6,7,8]. Rates of anemia in nursing home patients are estimated to be 48% to 63%, and anemic residents of long-term care have a higher associated mortality rate [9,10].
It is often difficult to determine the underlying cause of the anemia in older adults due to prevalence of polypharmacy and multiple medical comorbidities, which can complicate evaluation and diagnosis. Even with full evaluation, the cause of anemia remains unknown in 15% to 25% of cases. However, the recognition of anemia is important, as it may be the first sign of an underlying illness, such as gastrointestinal malignancy . Goals of anemia treatment should be to prevent worsening of the condition, slow progression, and promote improvement of outcomes .
Treatment and care of the elderly is further complicated by physical, psychological, and sociological changes associated with aging. Physical considerations include comorbid medical conditions, sensory loss, anorexia, reduced thirst, early satiety, and medication side effects. Common psychological manifestations of aging include cognitive impairment, delirium, depression, and psychiatric illness. Socioeconomic issues include poverty, lack of family support, isolation, dependency, substandard living conditions, and elder abuse. In order to successfully treat anemia in geriatric patients, consideration of these possible issues is essential.
Anemia is generally defined as a medical condition in which the number or function of erythrocytes or red blood cells (RBCs) is inadequate to meet tissue oxygenation needs. The body is unable to compensate for this reduction in the number of circulating erythrocytes.
The World Health Organization (WHO) defines anemia as a hemoglobin (Hgb) level less than 12 g/dL for women and less than 13 g/dL for men. An Hgb level of 10 to 12 g/dL is classified as mild anemia . However, it is important to note that the use of Hgb level to define anemia has been controversial. In countries in which nutritional deficiencies, infection, or congenital blood disorders are common, it may be difficult to apply a universal Hgb cutpoint . In addition, there appear to be racial differences in Hgb levels and the point at which symptoms of anemia emerge. Black patients in particular seem to tolerate a lower Hgb level than white patients. In general, black patients have a lower median Hgb and higher anemia prevalence. Further research is needed to determine if a different Hgb level would be appropriate to diagnose and begin treatment for anemia in the black population .
In the past, elderly persons with mild anemia (i.e., Hgb >10 g/dL) have not received much attention from the medical community. Clinicians traditionally have not treated mild anemia, as it was considered to be a natural consequence of aging. However, it is now known that even mild anemia is associated with increased hospitalization and mortality in the elderly .
Chronic severe anemia in the elderly may lead to cardiac functional abnormalities. The reduction in tissue oxygen delivery and the compensatory tachycardia that invariably follows may, in time, lead to impaired ventricular systolic function . Functional cardiac abnormalities occur when Hgb levels fall below 7–10 g/dL in patients without heart disease. In the presence of heart disease, the Hgb level should be kept above 10 g/dL .
Conceptually, the causes of anemia can be divided into four main categories: blood loss, hemolysis, bone marrow factor deficiency or suppression, and splenic sequestration, each of which may occur alone or concomitantly. Because splenic sequestration occurs most often in children with sickle cell anemia who are between the ages of 2 months and 4 years, it will not be discussed in detail in this course.
The most common causes of anemia in the elderly include gastrointestinal bleeding, renal insufficiency, chronic inflammation, blood disorder, medication adverse effects, drug/alcohol abuse, and dietary deficiency (Table 1) . Depending on the cause, anemia may be acute or chronic. Acute blood loss can create an emergency situation requiring immediate attention. In contrast, patients with chronic anemia lose blood over an extended period of time, and the risks are less immediate.
Blood loss commonly occurs in the gastrointestinal tract secondary to gastric ulcers, gastritis, colitis, diverticulitis, and cancer. Anemia may also develop secondary to hemolysis, or the destruction of erythrocytes characterized by RBCs' failure to live the usual 120 days. It can have various causes, ranging from genetic disorders to mechanical heart valve and medication side effects.
A reduction in RBC production can also result in anemia. This may be related to bone marrow suppression due to medication adverse effects and myelodysplasia, or decreased bone marrow production associated with aging. In some older patients, reduced kidney function will result in decreased erythropoietin production, which in turn causes decreased production of RBCs in the bone marrow.
Anemia of inflammation and chronic disease (AI/ACD) is commonly seen in older patients. It is defined as a low serum iron and RBC levels despite iron stores that are normal or high, the result of blocked delivery of iron to developing RBCs and reduced intestinal absorption .
Older adults tend to have increased levels of pro-inflammatory cytokines secondary to multiple comorbid illnesses. Cytokines are chemical messengers of the body that mediate immune or inflammatory response and include tumor necrosis factor, interleukin-1, and the interferons. Over time, the presence of these messengers reduces absorption of iron, decreases the release of iron, and interferes with RBC production . As a result, AI/ACD is significantly more common in older patients, particularly those with chronic disorders . AI/ACD may be diagnosed only when other etiologies of anemia are excluded. In difficult cases, bone marrow aspiration/biopsy may be necessary to confirm the diagnosis.
The cause of AI/ACD is uncertain and variable. It is now known that ACI may be the result of a wide range of medical conditions, including severe trauma, heart failure, diabetes, and acute or chronic immune activation . It is also important to note that anemia in elderly patients may be multifactorial—the result of a combination of chronic disease, blood loss, and/or vitamin deficiencies . In patients with true AI/ACD, the severity of the anemia correlates to the severity of the underlying medical condition. When the underlying condition is treated, AI/ACD usually improves .
A prospective, multi-institutional cohort study was performed to characterize anemia in elderly nursing home residents. In healthy younger adults, erythropoiesis increases in response to anemia or hypoxia. However, the study found that erythropoietic response is lower with advancing age, which may be in part due to unrecognized renal dysfunction . Lower responses were also associated with chronic conditions like rheumatoid arthritis and cancer.
As noted, chronic anemia in the elderly may adversely affect cardiac function . This is significant when establishing a treatment plan, as the presence of heart disease requires careful observation of Hgb levels. Chronic anemia can have other adverse effects on elderly patients, including extreme fatigue, impaired healing, and increased risk of hospitalization and death [1,16].
Nutrient-deficiency anemia is a significant cause of anemia, especially in the elderly. Iron, folate, and vitamin B12 deficiencies may be seen alone, but more often a combination of these deficiencies is present .
An estimated 15% to 23% of anemic elders have iron deficiency . Iron-deficiency anemia is characterized by depletion of iron stores. Microcytic, hypochromic (smaller and paler) RBCs are often present due to the decreasing iron supply. However, the presence of normal RBCs (normocytic anemia) does not exclude iron-deficiency anemia, as microcytosis is a late finding of severe iron deficiency. Elderly individuals may be at increased risk for decreased iron absorption due to medication side effects, chronic illness and inflammation, dietary iron deficiencies, and malabsorption.
Iron deficiency occurs when the rate of iron utilization by the body exceeds the rate of intestinal absorption and iron stores are depleted. This may be caused by inadequate nutritional intake, impaired absorption of iron, or physiological losses. Serum ferritin concentrations of 25 to 45 mg/dL are suspicious for iron-deficiency anemia. Levels greater than 100 mg/dL indicate sufficient iron stores and the likelihood of iron-deficiency anemia is reduced. However, infectious or inflammatory responses will increase serum ferritin concentration, making measurements potentially unreliable. In patients with infectious or inflammatory disorders, plasma transferrin receptor concentration may be a more useful measure.
The most common cause of iron-deficiency anemia in the elderly is blood loss from the gastrointestinal tract. Blood loss from the gastrointestinal tract may be chronic or acute depending on the underlying etiology. It may be the result of nonsteroidal anti-inflammatory drug (NSAID) use, a gastric ulcer, colon cancer, diverticulosis, or angiodysplasia (i.e., vascular malformation in the gastrointestinal tract). In one study, gastrointestinal malignancy was present in 6% of patients with iron-deficiency anemia . Referral to gastroenterology for endoscopic evaluation is crucial for all patients with iron-deficiency anemia, and colonoscopy is recommended every 10 years beginning at 50 years of age to evaluate for possible malignancy as part of routine health maintenance and prevention . Stool should be tested for occult blood in the initial anemia work-up. It is important to also consider other potential causes of microcytic anemia during the evaluation of elderly patients with iron-deficiency anemia. For example, heavy metal poisoning may be an etiologic factor for anemia, and hypochromic, microcytic anemia may be associated with lead poisoning.
It is imperative to evaluate the patient with iron-deficiency anemia for underlying conditions. Medical conditions or medications that decrease gastric pH reduce the absorption of iron, which presents as iron-deficiency anemia. In older adults, atrophic gastritis, which causes chronic decreased gastric acid production secondary to damage to the acid producing cells of the stomach, should be considered. Commonly used medications, including antacids, proton pump inhibitors, and H2 histamine blockers, may contribute to the development of anemia.
Vitamin B12 (also called cobalamin) is necessary for DNA synthesis, RBC maturation, and normal functioning of the neurologic system . Older adults are at increased risk for developing vitamin B12 deficiencies for many reasons, including atrophic gastritis, which results in a reduced ability to absorb vitamin B12 from food sources. Vitamin B12 deficiency can also result from inadequate dietary intake and defects in metabolism. In addition to anemia, vitamin B12 deficiency can cause damage to the brain and nervous system.
Several medications are associated with increased risk of vitamin B deficiencies, and due to the higher rate of polypharmacy and chronic conditions among the elderly, drug-induced vitamin B12 deficiency is a serious concern. Long-term use of the antibiotic chloramphenicol may inhibit RBC response to vitamin B12 supplements in some patients . Proton-pump inhibitors, such as omeprazole, and H2 receptor antagonists, such as ranitidine, may be prescribed long term for gastroesophageal reflux disease or peptic ulcer disease; both of these drug classes slow the release of gastric acid, thereby potentially interfering with the absorption of vitamin B12, particularly in patients with already low stores [22,23,24]. However, studies of older adults have failed to conclusively determine if these acid-lowering agents are a significant cause of vitamin B12 deficiency [23,24,25].
Metformin, a biguanide used to treat diabetes, has also been associated with vitamin B12 deficiencies, and an estimated 10% to 30% of metformin users have reduced vitamin B12 absorption [26,27,28,29]. It is believed that impaired calcium availability due to metformin activity may interfere with the calcium-dependent process of vitamin B12 absorption . Dose and duration of use appear to be most strongly correlated with risk of vitamin B12 deficiency. For this reason, patients taking metformin to control their diabetes should be closely monitored for signs of vitamin deficiency.
Pernicious anemia is an autoimmune disease that may be a common cause of B12 deficiency in older adults . It is characterized by a decrease in RBCs resulting from impaired intestinal absorption of vitamin B12, caused by autoimmunity against intrinsic factor or gastric parietal cells (which produce intrinsic factor). Intrinsic factor is necessary for the absorption of vitamin B12, and decreased production of intrinsic factor leads to reduced absorption of vitamin B12 .
Many other conditions have been associated with vitamin B12 deficiency. Atrophic gastritis, a condition common in elders, can cause pernicious anemia and intrinsic factor deficiency secondary to damage to the parietal cells of the stomach. Malabsorption of vitamin B12 and other nutrients may also be caused by Crohn's disease, Whipple's disease, celiac disease, or gastrectomy .
The primary natural sources of dietary vitamin B12 are animal products, including fish and shellfish, beef, poultry, pork, eggs, and dairy products . However, fortified cereals also usually contain 100% of the recommended daily value of vitamin B12. Strict vegetarians and particularly vegans, who consume no animal products, are at an increased risk of insufficient intake of vitamin B12, and these patients may benefit from vitamin B12-fortified foods, oral vitamin B12 supplements, or vitamin B12 injections.
Folate (also known as folic acid or vitamin B9) is a B vitamin that is necessary for RBC production. Folate deficiency usually results from inadequate dietary intake or malabsorption and is more common in the elderly and chronically ill. In adults, it often occurs with alcoholism and during pregnancy and breastfeeding . Less often, folate deficiency may develop in individuals taking medications such as methotrexate, phenytoin, and trimethoprim, which interfere with the absorption of folate [31,32]. Methotrexate in particular is used for a wide variety of conditions (including rheumatoid arthritis, lupus, psoriasis, and asthma) that may be more common in elderly patients. Dialysis patients are also at risk of deficiency, as folate is lost in dialysis fluid .
Body stores of folate range from 500–20,000 mcg. It is necessary for humans to absorb 50–100 mcg of folate daily to replenish losses through bile and urine. Food sources of folate include green vegetables, yeast, liver, beans, whole grains, and wheat bran. Many foods are also fortified with folate, including some breakfast cereals, rice, breads, and pasta . Signs and symptoms of folate deficiency (e.g., weakness, fatigue, difficulty concentrating, dyspnea) develop gradually and are usually apparent after about 4 months.
Older patients may develop folate deficiency for a variety of reasons. Hyperutilization of folic acid by metabolic processes may be caused by malignancy, Crohn's disease, rheumatoid arthritis, or medication side effects. Elderly persons may have difficulty chewing and swallowing certain foods, causing various nutrient deficiencies. Food preparation is also a consideration, as folate is destroyed by excessive heat and dilution. As with vitamin B12, polypharmacy and drug-induced deficiency are a greater concern in older patients.
Serum homocysteine is elevated in the majority of patients with folate and B12 deficiencies. Homocysteine is an amino acid in the blood, and studies have shown that elevated homocysteine levels are associated with a higher risk of cardiovascular disease . However, studies of the effect of folic acid and B vitamin supplementation on cardiovascular events found that, despite a significant decrease in serum homocysteine, the incidence of cardiovascular events did not decrease [4,33].
Folate and vitamin B12 deficiency both cause a macrocytic anemia, and one cannot be differentiated from another by laboratory examination of the cells. Some patients may remain asymptomatic despite low Hgb levels due to slow progression of the disease.
While a diet rich in folate has been shown to be protective against certain types of cancer, particularly colorectal cancer, very high levels of the nutrient have also been associated with an increased risk of developing cancer [34,35]. High levels of folate, often the result of oversupplementation, may facilitate hyperproliferation, which is present in most dysplastic and malignant neoplasms . If any dysplastic cells are present, even if very small or undetected, high levels of folate may accelerate the disease process and result in more aggressive forms of cancer. This so-called "dual effect" of folate can make recommending a certain level of supplementation difficult. More research is necessary to determine if the bioavailability and action differs between the dietary and pharmaceutical forms of the vitamin and if there are certain populations who may safely take a certain amount of folate supplementation or fortification.
Bone marrow is a blood-forming (hematopoietic) organ responsible for the production of most of the cellular components of the blood, including erythrocytes, leukocytes, and platelets. As an individual ages, he or she will produce a decreased amount of functional bone marrow, and disorders of hematopoiesis are more common in the elderly. Myelodysplastic syndromes (MDS) are one such group of disorders and a cause of anemia in older patients, although it is relatively uncommon. These disorders are characterized by one or more peripheral blood cytopenias resulting from bone marrow dysfunction . According to the French-American-British (FAB) classification system, MDS is further classified according to cellular morphology, etiology, and clinical presentation as :
Refractory anemia with ringed sideroblasts
Refractory anemia with excess blasts
Refractory anemia with excess blasts in transformation
Chronic myelomonocytic leukemia
In 2008, the WHO revised its classification system for MDS, which is now based more on the results of genetic testing than previous systems . The main differences include the elimination of the refractory anemia with excess blasts in transformation category, which is considered acute leukemia, and the addition of several subcategories and new categories. The WHO organizes MDS into the following classifications [32,36]:
Refractory cytopenia with multilineage dysplasia
Refractory anemia with ringed sideroblasts
Refractory anemia with excess blasts
Myelodysplastic syndrome, unclassifiable
Myelodysplastic syndrome associated with del(5q)
As noted, myelodysplasia is more common in elderly patients, and more than 75% of patients with MDS are older than 60 years of age at diagnosis . Patients may be asymptomatic, and the disease is often found as the result of routine blood tests. When present, signs and symptoms include fatigue, pallor, frequent infections, easy bruising, and petechiae. An estimated 30% of cases will progress to acute leukemia .
Anemia dominates the early course of MDS. Other key characteristics include macrocytosis, neutropenia, and thrombocytopenia. A poor prognosis is associated with advanced age, severe thrombocytopenia, and neutropenia.
Kidney function and glomerular filtration rate (GFR) naturally decreases with age, and it may be further decreased in the presence of chronic illnesses such as hypertension and diabetes, the two main causes of chronic kidney disease. With declining kidney function there is a decreased production of erythropoietin from the kidneys, and this is the primary etiology of anemia associated with chronic kidney disease. It can be difficult to differentiate the effects of normal aging on the kidneys from chronic kidney disease. Although GFR decreasing with age is considered normal, the diagnostic criteria for chronic kidney disease are not modified according to a patient's age. Chronic kidney disease is defined as kidney damage or a GFR less than 60 mL/minute/1.73 m2 for more than 3 months . It is further staged according to severity of GFR impairment and other symptoms (Table 2).
STAGES OF CHRONIC KIDNEY DISEASE
|Stage||Glomerular Filtration Rate (mL/min/1.73 m2)||Description|
|1||>90||Normal or increased GFR, with other evidence of kidney damage|
|2||60–89||Slight decrease in GFR, with other evidence of kidney damage|
|3||30–59||Moderate decrease in GFR, with or without other evidence of kidney damage|
|4||15–29||Severe decrease in GFR, with or without other evidence of kidney damage|
|5||<15||Established renal failure|
Anemia is considered an indication of end-stage kidney disease, but women, diabetics, and African Americans may develop this complication at an earlier disease stage . As noted, the primary etiology of anemia in chronic kidney disease is erythropoietin deficiency, but other causes should be evaluated as there may be a combination of factors contributing to the anemia. Other potential causes include:
Chronic blood loss
Vitamin B12 or folate deficiency
Hemolytic anemias occur as a result of deficiency of RBCs secondary to premature destruction. Hemolysis causes RBCs to live less than 120 days, their usual lifespan. The bone marrow is not able to increase production to compensate for the loss of RBCs, resulting in anemia . Hemolytic anemias are usually categorized as inherited (e.g., sickle cell anemia) or acquired (e.g., the result of an immune disorder or infection). Some patients will have no known cause .
Sickle cell anemia is an inherited cause of hemolysis in which a genetic abnormality results in alteration of the Hgb structure, known as HgbS. The RBCs have an atypical response to hypoxia, and the cells develop a characteristic rigid sickle shape. The abnormal blood cells deliver less oxygen to the body tissues. Sickle-shaped Hgb can occlude the blood vessels, causing pain, organ damage, or stroke. The sickle cells usually die after 10 to 20 days, and anemia results .
Sickle cell disease occurs more often in persons with ancestors from sub-Saharan Africa, the Mediterranean, India, and Saudi Arabia [40,41]. In the United States, the rates are the highest for black individuals, with 1 in 500 black or African Americans having sickle cell disease [41,42]. If both parents carry the sickle cell trait, there is a 1 in 4 chance of having a child with sickle cell anemia, but carriers of sickle cell trait are generally asymptomatic. The lifespan of sickle cell patients is greatly reduced, so this type anemia is rarely seen in geriatric patients.
Thalassemias are another inherited hemolytic anemia. It is characterized by a genetic defect or deletion that causes an abnormal synthesis of one of the Hgb protein chains (alpha or beta) . The alpha type is more common among African and South Asian persons, while the beta type is endemic to Mediterranean regions [43,44]. Thalassemia major occurs when the gene is inherited from both parents; thalassemia minor occurs if the gene is inherited from one parent. Severe thalassemias can cause a premature death, often between 20 and 30 years of age, but less severe forms have a favorable prognosis. Laboratory tests are usually necessary for diagnosis, but genetic studies can also be helpful .
In acquired hemolytic anemia, the body is producing normal RBCs, but the cells are being damaged. Potential causes of hemolysis include mechanical heart valves, immune disorders, infections, hypersplenism, drug or transfusion reactions, chronic liver disease, congestive heart failure, leukemia, and lymphoma.
Aplastic anemia is a life-threatening condition that occurs due to unexplained bone marrow failure. The bone marrow's stem cells are damaged as the result of an inherited condition or may be caused by an acquired condition, including an autoimmune disorder, exposure to toxic chemicals, chemotherapy or radiation exposure, infection, or in rare cases, pregnancy . In some patients the cause of aplastic anemia remains unknown. Hereditary aplastic anemia is very rare; the acquired type is more prevalent. However, only 3 of every 1 million Americans will be diagnosed with any type of aplastic anemia annually . As with other anemias, patients with aplastic anemia are susceptible to bleeding, fatigue, and infections. Pancytopenia is present when there are low counts of RBCs, WBCs, and platelets. The diagnosis of aplastic anemia is confirmed by bone marrow examination.
Many cases of anemia will be found during routine blood tests done for other reasons. The initial laboratory evaluation of anemia will be determined by the patient's medical history and physical. When completed, the laboratory evaluation should include:
Complete blood count (CBC)
Stool for occult blood
The CBC is important for the diagnosis of anemia and for monitoring disease progression and treatment efficacy. When assessing the elderly anemia patient, the most important components of the CBC are :
Erythrocyte (RBC) count: Reports the total number of RBCs per liter of whole blood.
Normal range for men: 4.7–6.1 million cells/mcL
Normal range for women: 4.2–5.4 million cells/mcL
Hgb: Measures the amount of hemoglobin present in the blood. Dehydration may produce a falsely high Hgb.
Normal range for men: 13–17 g/dL
Normal range for women: 12–16 g/dL
Hematocrit (HCT): Packed cell volume in proportion to blood volume.
Normal range for men: 40% to 52%
Normal range for women: 36% to 48%
Mean cell (corpuscular) volume (MCV): Measures the average size of RBCs, a diagnostic parameter for evaluating anemia, and differentiates microcytic and normocytic anemia in the elderly.
Normal range: 81–100 fL
Macrocytosis: Greater than 100 fL with large RBCs
Microcytosis: Less than 81 fL with small RBCs
Mean cell hemoglobin (MCH): Average amount of Hgb in an RBC.
Normal range: 27–34 Hgb/cell
Mean cell hemoglobin concentration (MCHC): Average concentration of Hgb in an RBC.
Normal range: 30% to 36%
RBC distribution width (RDW-CV): Measures variations in the size of RBCs.
Normal range: 12% to 14%
Leukocyte (white blood cell) count: Reports the number of leukocytes in the blood; the differential includes different types of leukocytes (i.e., neutrophil, eosinophil, basophil, lymphocyte, monocyte).
Normal range: 4,500–10,000 cells/mcL
Thrombocytes/platelet count: Number of platelets present.
Normal range: 150,000–450,000 cells/mcL
Clinicians should remember that laboratory values are not treated, patients are. Any abnormal laboratory results should be correlated with the physical condition of the patient and the patient's goals. Furthermore, different laboratories may use different reference values.
Symptoms of anemia may occur when the Hgb falls below 11 g/dL; when Hgb falls below 8 g/dL, the anemia is life-threatening. The CBC provides valuable insight into the type of anemia. If leukopenia and thrombocytopenia are present along with anemia, a myelodysplastic disorder is suspected. The MCV reveals the size of the cells, leading to the classification of normocytosis, microcytosis, or macrocytosis and indicating potential causes (Table 3).
CATEGORIES OF MEAN CORPUSCULAR VOLUME AND ASSOCIATED CAUSES OF ANEMIA
|Category||Mean Corpuscular Volume||Possible Causes of Anemia|
|Microcytosis||<81 fL with small red blood cells||
|Normal range||81–100 fL||
|Macrocytosis||>100 fL with large red blood cells||
Examination of a peripheral blood smear for morphologic abnormalities of RBCs (and for leukocytes and platelets as well) should be part of any evaluation of anemia. Anisocytosis indicates excessive numbers of RBCs with varying sizes; poikilocytosis denotes variation in shape and contour of RBCs . Reticulocytes, which are young RBCs that mature in the marrow before release into the circulation, will appear in the blood in large numbers when there is accelerated RBC production, as occurs with hemolysis. A normal reticulocyte value is 0.5% to 1.5%; however, the reticulocyte count may be elevated in an anemic patient (reticulocytosis), indicating an erythropoietic response to the anemia . Reticulocytosis may also raise suspicion for hemolytic anemia or increased RBC destruction. A low reticulocyte count (reticulocytopenia) usually indicates decreased RBC production and may point toward aplastic anemia, bone marrow depression, nutritional anemia, or ACI.
The iron profile is a crucial component to anemia evaluation. Before iron replacement therapy is initiated, the patient's iron level should be measured and documented. The serum iron level is an indicator of the amount of iron bound to transferrin in the blood. The iron profile will measure:
Total serum iron
Normal range for men: 60–176 mcg/dL
Normal range for women: 45–170 mcg/dL
Total iron binding capacity
Normal range: 250–450 mcg/dL
Unsaturated iron binding capacity
Normal range: 100–400 mcg/dL
Normal range: 20% to 50%
Normal range for men: 12–350 ng/mL
Normal range for women: 12–200 ng/mL
The iron profile, including the ferritin level, will give information about the iron availability, absorption, and iron stores of the body. Serum ferritin levels of 12–100 ng/mL can be present in both iron-deficiency anemia and AI/ACD . Low serum ferritin levels are indicative of iron-deficiency anemia, and these patients should be evaluated for occult gastrointestinal bleeding from a malignancy or other cause.
A vitamin profile may also be necessary, as macrocytic anemia occurs with both folate and vitamin B12 deficiencies. As noted, low levels of folate have been associated with homocysteine accumulation, a risk factor for cardiovascular disease. Although lowering homocysteine levels may not improve outcomes, its presence as a risk factor should be considered. Replacing folate without replacing vitamin B12 may mask a B12 deficiency, leaving the patient at risk for neurologic complications. The vitamin profile may include measurements of:
Folate (vitamin B9)
Normal range: 4–20 mcM
Vitamin B12 (cobalamin)
Normal range: 200–900 pg/mL
Normal range: 73–271 nM
Normal range: 5.1–13.9 mcM
Serum methylmalonic acid can be a useful diagnostic tool in identifying vitamin B12 deficiency when the B12 level is in the low-normal range (200–500 pg/mL), which can be particularly helpful for older adults, who experience symptoms at this level with greater frequency than younger patients. Methylmalonic acid begins to rise when the B12 levels fall below 400 pg/mL. The methylmalonic acid is normal in folate deficiency but may be elevated in renal insufficiency. Serum homocysteine and methylmalonic acid levels are high in 90% of patients with vitamin B12 deficiency .
Stool specimen for occult blood is another vital test for evaluation of anemia, as gastrointestinal bleeding is often a major contributing factor. Gastrointestinal bleeding may be intermittent, so evaluation of three different bowel movements is recommended. In preparation for the test, patients should stop taking iron supplements for 10 days and avoid red meat and food with red dye for 3 days prior to testing.
If the patient is positive for blood in the stool, gastroenterology consult is indicated. The patient will need endoscopy or colonoscopy to locate the source of the bleeding; blood in the stool may originate from hemorrhoids or other less serious problems. Alternatively, blood in the stool can be a sign of gastrointestinal malignancy.
Erythropoietin level is not ordered frequently, but it is used in patients with unexplained polycythemia (abnormally elevated concentration of RBCs). The erythropoietin level is also reduced in chronic kidney disease and myelodysplasia. The normal range is 4.5–21.3 mU/mL. Patients with high erythropoietin levels and anemia will most likely not respond to erythropoietin-stimulating agents (ESAs). Measuring serum erythropoietin levels is of little diagnostic utility in patients with chronic kidney disease .
In cases of unexplained anemia, a referral to a hematologist is necessary for bone marrow aspiration and biopsy. Bone marrow aspiration/biopsy is necessary to evaluate cytopenias, leukocytosis, and thrombocytosis. If conducted, this procedure is generally performed in the outpatient setting.
For patients without a definable cause for the anemia, additional laboratory tests may be necessary for follow-up. If an identifiable and treatable etiology of the anemia is not found, a hematology consult is essential. Other laboratory tests that may be ordered in cases of anemia of unknown etiology include:
Liver function profile
Serum levels of heavy metals (e.g., arsenic, lead)
Medical records and past medical history help the clinician to determine if the anemia is chronic or acute, hereditary or acquired. If a patient is known to have had a normal CBC in the past, the anemia is most likely not caused by an inherited or congenital disorder. A complete patient history will provide information regarding chronic illness, history of anemia, specialty consults, and history of blood transfusions. Elderly patients with dementia may be unable to provide an accurate medical history. In these cases, caregivers and family may be good sources of information. If certain tests and diagnostics have already been completed, they may not need to be repeated.
The medical history should include an inquiry as to prior history of anemia and whether there is existing laboratory data that could establish prior Hgb levels. This will help to determine if the present condition represents an acute or chronic anemia. One should also assess the patient for:
Chronic medical illness
Chronic kidney disease
Use of NSAIDs, aspirin, and/or blood thinners
Family history of anemia
Exposure to toxic chemicals
Loss of functioning bone marrow
Increase in chronic illness
Elderly patients with anemia may have vague, non-specific symptoms, and because the symptoms are non-specific, they are usually not helpful in differentiating between the types of anemia. Older patients are at greater risk for falls, cognitive decline, fatigue, and weakness as a result of advanced age, making the identification of anemia even more complicated . Patients with mild anemia may remain asymptomatic. Aside from fatigue and weakness, other symptoms may include tachycardia, bradycardia, dyspnea, chest pain, dizziness, headache, cold hands and feet, restless legs syndrome, and tarry stools. On occasion, patients may complain of visible changes in or discomfort of the tongue or lips, indicative of atrophic glottis and cheilitis. The severity of symptoms is dependent on the rapidity of onset, degree of anemia, physical status, and age of the patient . Because anemia may be multifactorial, complete evaluation is necessary.
Pica may develop in some anemic patients. Pica is a condition whereby the patient has an unusual craving to eat non-food items, such as dirt, ice, starch, or clay, and is associated with both mineral deficiency (including iron-deficiency anemia) and mental health conditions. Pagophagia, a craving (pica) for ice, is present in about 50% of patients with iron deficiency, even in the absence of frank anemia . The consumption of non-food items by the patient should be specifically inquired about as it may not be discovered during a routine history and physical examination.
Patients with symptomatic anemia may present with multiple vague symptoms that do not point to any one diagnosis. To fully evaluate these symptoms, physical assessment and laboratory evaluation are necessary. Healthcare providers who work with the demented elderly should become adept at detecting medical conditions for patients unable to provide any history or symptomatology.
The physical assessment of the elder should focus on differentiating normal aging changes from pathology. The physical assessment of an anemic elder begins with visual evaluation of the patient's general physical and mental condition. This includes signs of malnourishment, pallor, breathing difficulties, and edema or ascites that may indicate chronic liver or kidney disease. Many observations can be made during the review of systems and medical history taking. The patient's cognitive function should also be assessed, including ability to answer questions appropriately, delayed responses, and signs of compensating for a cognitive deficit.
Basic measurements lay the foundation for the physical assessment. The vital signs, oxygen saturation, height, and weight give valuable clues to the etiology of anemia. If the patient is underweight, with a body mass index of 18.5 or less, suspicion of nutrient-deficiency anemia is increased.
The major clinical signs in the anemic patient are secondary to hemodynamic changes and tissue hypoxia. Acute blood loss causes hypovolemia, hypotension, and if severe enough, signs and symptoms of shock. Over time, decreased blood volume will eventually cause orthostatic hypotension and tachycardia. This change in orthostasis is especially dangerous in elders, as it predisposes them to falls and injury. A bounding or rapid pulse may indicate that the cardiovascular system is compensating for low Hgb. Oxygen saturation may be decreased secondary to low Hgb, and increased respirations may be observed.
In addition to pallor of the skin, the inferior conjunctiva of the eye may appear pale. The tongue may appear smooth and swollen, with loss of papillae (glossitis). Angular stomatitis (cheilitis) causing irritation and fissuring of the corners of the lips may indicate nutritional or iron deficiency. Jaundice could indicate liver failure or hemolytic anemia.
Assessment of the cardiovascular system may reveal tachycardia, heart murmurs, increased peripheral edema, dyspnea, and orthopnea, which will be more pronounced in patients with chronic heart disease. Anemia may precipitate a myocardial infarction in patients with coronary artery disease or the worsening of angina due to the decreased oxygen carrying capacity of Hgb. In patients with peripheral arterial disease, intermittent claudication may develop or worsen. In patients with cerebrovascular disease, severe anemia may lead to transient ischemic attacks and cognitive decline.
Evaluation of the fingernails may reveal splitting and fraying associated with folate deficiency. Spooning of the nails (nails that grow upward) can indicate vitamin B12 deficiency.
Abdominal scars may be present due to gastrectomy or ileal resection, which gives information about possible malabsorption or gastrointestinal disorders. Older patients may give inaccurate medical histories, so these clues can be quite useful. There may be symptoms of anorexia, weight loss, constipation, and nausea.
Neurologic examination may reveal memory deficits, paresthesias, and unsteady gait in patients with B12 deficiency anemia. Vitamin B12 deficiency should be considered for patients with even minimal neurologic symptoms. In later stages of vitamin B12 deficiency, the neurologic symptoms worsen and may become severe.
Close monitoring of pertinent laboratory values is necessary to evaluate patients' response to treatment. If a patient does not respond to the prescribed treatment, further evaluations and diagnostics may be needed to detect anemia of multiple etiologies.
Treatment of anemia in elderly patients is largely dependent upon the etiology and the clinical signs and symptoms of the disease. For the most part, treatment of the underlying cause should result in improvements in Hgb levels. However, for the many patients for whom the cause is unknown, treatment is controversial. Decisions regarding the treatment plan should be individualized and based on a variety of factors, including patient goals, functional status, and presence of comorbidities . Although treatment with ESAs may result in significant improvements in Hgb levels, this approach has not been fully studied in patients with unexplained anemia and there is no evidence of pharmacologic treatment improving elderly patients' quality of life, physical function, or disability . Due to the low risk of adverse effects, lifestyle interventions are often a first approach, including improvements in diet and vitamin supplementation. In most patients with mild disease, this may be sufficient.
As discussed, in cases of AI/ACD, the stabilization of the underlying chronic illness should improve Hgb and symptoms of anemia. This should be the first approach and should include assessment and treatment of other complicating factors, including iron deficiency, malignancies, or blood loss . However, if the patient is experiencing impaired quality of life as a result of anemia symptoms or if the presence of anemia could complicate other age-related disorders, treatment with an ESA, such as epoetin alfa, and/or blood transfusion should be considered.
ESAs are used in the treatment of many anemias, regardless of etiology, and they have been found to be effective in improving Hgb levels in elderly patients. The overall goal of ESA treatment is to improve the Hgb level to the point that blood transfusion can be avoided [54,55]. Usually, ESAs are considered when the Hgb is less than 10 g/dL. However, more research in elderly patients is necessary to determine if this applies similarly to older adults. A randomized, double-blind, placebo-controlled study was conducted to evaluate the efficacy of epoetin alfa in the treatment of anemia in women older than 65 years of age . Among this group, epoetin alfa was well tolerated, and the treatment group experienced an increase of 2 g/dL or more in their Hgb levels. Researchers found a direct correlation between Hgb levels and improvements in measures of fatigue and quality of life . Review of mortality information related to Hgb levels indicates that levels greater than 13 g/dL are associated with poor outcomes, while Hgb levels of 9.5–11.5 g/dL are associated with better outcomes .
ESAs are associated with significant adverse effects, particularly in patients with cancer or chronic kidney disease. In all patients, ESAs are associated with an increased risk for serious cardiovascular events, thromboembolic events, stroke, and mortality when administered to target hemoglobin levels greater than 11 g/dL . Due to the risk of deep vein thrombosis, all patients who require surgery should be given prophylaxis prior to the procedure. Prescribing of ESAs should be restricted to clinicians experienced in use and monitoring of the treatment. Because there is an increased risk of death, serious cardiovascular events, hypertension, thrombosis, and progression of certain cancers, patients should be closely monitored. In addition, patients must understand the risks associated with this treatment. Quality of life measures should be considered.
The recommended dosage of epoetin alpha is 100–150 U/kg subcutaneously three times per week along with supplemental oral iron . If no improvement is seen in 6 to 8 weeks, this dose may be increased to daily administration or to 300 U/Kg three times weekly. A once weekly dose of 30,000 to 40,000 U subcutaneously is also available. If the patient has no response to treatment after 12 weeks, it is unlikely to be clinically useful .
In order for treatment with ESAs to be effective, iron supplementation to ensure adequate stores is necessary. Supplementation should maintain a transferrin saturation of 20% or greater and a serum ferritin level of 100 ng/mL or greater .
Because the major cause of iron deficiency is overt or occult blood loss, the first step should be to identify and treat the source of the iron or blood loss, which should improve Hgb levels and symptoms of anemia. Any medications that may be blocking iron absorption should be discontinued. In cases of malnutrition or non-drug-induced impaired gastrointestinal absorption of iron, oral supplementation may be indicated. The recommended supplement for the treatment of iron deficiency in older adults has not been established. The adult dose is usually 150 to 200 mg/day of elemental iron; however, one study of patients older than 80 years of age found that daily doses of 15 mg or 50 mg liquid ferrous gluconate or 150 mg ferrous calcium citrate tablets resulted in similar outcomes, with significant increases in Hgb evidenced in all three treatment groups . The lowest possible dose should be used first, with gradual titration, if necessary. If a patient is unable to take even the smallest dose of oral iron due to adverse effects (e.g., nausea, constipation, vomiting) or if improvement in Hgb cannot be obtained by oral supplementation (e.g., continued bleeding), parenteral iron therapy may be appropriate.
In 2013, the U.S. Food and Drugs Administration approved a ferric carboxymaltose injection (Injectafer) for the treatment of iron-deficiency anemia in patients who have intolerance to oral iron or have had an unsatisfactory response to oral iron . This parenteral iron replacement product is given as a single dose of up to 750 mg of iron via an IV push injection or over a 15 minute infusion followed by a second dose 7 days later for a total treatment of up to 1500 mg of iron .
Improvements in patient functioning, including less fatigue, resolution of pica, and increased participation in activities of daily living, should be seen within the first week. The Hgb level will rise more slowly, with full resolution expected within 6 to 8 weeks .
For patients low in vitamin B12 or folate, replacement therapy can be started immediately. Vitamin B12 supplements are available in oral, sublingual, intranasal, and injectable formulations. Traditionally, vitamin B12 replacement consisted of a series of injections of cyanocobalamin. However, a meta-analysis found that high daily doses (1000 mcg) of oral vitamin B12 were as effective as intramuscular injections .
Folate and vitamin B12 cannot be synthesized by the body and require daily intake. There is some concern that folate supplementation may "mask" a vitamin B12 deficiency; therefore, clinicians should screen older patients for vitamin B12 deficiency prior to initiating folic acid supplementation . Folate deficiency is mainly treated using supplementation of the vitamin. Most multivitamin preparations contain 400 mcg of folate, but this dosage may not be sufficient in cases of malabsorption or drug-induced deficiencies. Intake of folate should not exceed 1,000 mcg/day.
Treatment of MDS generally consists of supportive care, including transfusion of RBCs, which temporarily corrects the low blood counts. Platelet infusions become less effective over time and are associated with a risk of alloimmunization . Frequent transfusions can cause an iron overload, which can damage the liver and other organs; iron overload may become a problem after as few as 10 transfusions. When the serum ferritin level is between 1,000 and 2,000 ng/mL, the patient may require iron chelation therapy with subcutaneous or oral deferasirox or subcutaneous deferoxamine and vitamin C [32,55].
An ESA (e.g., epoetin alpha 150–300 mcg/kg/day) may be used in patients with a low erythropoietin level and is most useful in patients who do not yet require transfusion and patients who have a serum erythropoietin level less than 200 mU/mL. Other possible treatments of MDS include growth factor, chemotherapy, and bone marrow or stem cell transplantation.
The mainstays of treatment of anemia in chronic kidney disease patients are ESAs and iron supplementation . In 1989, the FDA approved the use of epoetin alpha for use in anemia of chronic kidney disease. Response to treatment with ESAs is inhibited in patients with kidney disease, and increased doses may be necessary to obtain an adequate response. The recommended initial dose is 50 to 100 U/kg per week or 10,000 U subcutaneously once weekly, with adjustment of the dose based on subsequent Hgb levels, response to treatment, and development of adverse side effects . As discussed, for ESA treatment to be effective, concurrent iron supplementation is also necessary.
However, the severe adverse effects of epoetin alpha and other ESAs have made their use complicated . Studies of have shown increased thromboembolic events, tumor progression, and cardiovascular events when Hgb levels are greater than 12 g/dL [51,64]. The FDA has issued a black box warning for epoetin alpha regarding the increased risk of death, serious cardiovascular events, and stroke in patients with chronic kidney disease with Hgb levels of 11 g/dL or greater . Although no optimal dose or Hgb target has been established for patients with kidney disease to prevent these adverse events, an Hgb level that raises more than 1 g/dL in one week may indicate an increased risk and should initiate a reduction in ESA dose . The lowest possible dose of ESA to prevent blood transfusion should be used.
Treatment of sickle cell anemia involves the use of hydroxyurea therapy, amelioration of pain, and other complications and supportive care. Blood transfusions are not used to treat normal anemia and pain associated with sickle cell disease, but it may be used during pregnancy or in cases of severe acute anemia or acute chest syndrome . However, patients who receive multiple transfusions are at risk for alloimmunization and iron overload. Iron chelation therapy may be necessary to prevent damage to the organs due to high iron levels. Allogeneic bone marrow transplant may produce a cure in a small number of patients .
Treatment of thalassemia consists of blood transfusions, iron chelation therapy, folic acid supplements, and bone marrow and stem cell transplant, depending on the type of thalassemia diagnosed . Some will require splenectomy.
The goal of treatment of aplastic anemia is to control symptoms and prevent complications. Initial treatment includes blood and platelet transfusions and IV antibiotics. While immunosuppressive drugs are effective in treating aplastic anemia, these medications further weaken the immune response, leaving the patient at risk of complications. ESAs and colony-stimulating factors are also used . For severe cases, an allogeneic bone marrow transplant may be advised. However, it is important to note that elderly patients may be unable to tolerate the preparation for transplant and are at an increased risk for complications. If left untreated, death will usually occur rapidly.
For cases of acute blood loss, as in trauma or surgery, a blood transfusion is the standard treatment for patients willing to receive blood and blood products. In addition, blood transfusions are indicated in the treatment of a wide variety of anemias in elderly patients. For chronic anemia, which may be caused by myelosuppression, inflammation, infection, or malignancy, a blood transfusion is not recommended. In patients with chronic anemia, blood transfusion causes a temporary increase in Hgb but fails to treat underlying condition(s) . Transfusion of blood products is generally reserved for patients with an Hgb level of 8 g/dL or less, due to risks of infection, volume overload, and transfusion reactions .
As noted, iron overload and clinical signs of hemochromatosis may occur with repeated blood transfusions. The excessive iron builds up in organs and tissues, especially the liver. Signs and symptoms of hemochromatosis may include joint paint, fatigue, generalized weakness, weight loss, and abdominal pain. Due to the potential hazards of iron overload on the body organs and tissues, iron should never be prescribed prior to laboratory assessment of iron stores of the body.
In patients with terminal disease, blood transfusions may be used to palliate the symptoms associated with anemia. Blood transfusions have been found to provide some relief from anemia symptoms (e.g., fatigue, dyspnea, weakness) and improved quality of life for patients suffering from cancer or terminal illness . Again, this is a palliative care technique and will not be curative or a long-term solution. In fact, it is important to remember that a blood transfusion has the potential to prolong pain and suffering at the end of life and to give patients and/or their families false hope. A risk and benefit analysis should be performed prior to initiating transfusions for these patients.
Language and cultural barriers have the potential for far-reaching effect, given the growing percentages of racial/ethnic populations. As noted, patient understanding of the causes and available treatments is an essential component of caring for the geriatric patient with anemia, and it should be assured that all patients have a clear understanding of the concepts discussed. When there is an obvious disconnect in the communication process between the practitioner and patient due to the patient's lack of proficiency in the English language, an interpreter is required.
Clinicians should use plain language in their discussions with their patients who have low literacy or limited English proficiency. They should ask them to repeat pertinent information in their own words to confirm understanding, and reinforcement with the use of low-literacy or translated educational materials may be helpful.
Patient H is a white woman, 89 years of age, who resides in a skilled nursing facility. She is being evaluated due to an Hgb level of 8.1 g/dL. She is ambulatory with a rolling walker, generally alert, and oriented with some mild cognitive impairment. She is compliant with medical treatments and takes medications as prescribed. Her medical history is positive for congestive heart failure, chronic obstructive pulmonary disease (COPD), chronic kidney disease, and osteoarthritis. She is oxygen dependent on 2 L/minute per nasal cannula. She is bright and outgoing and verbalizes multiple vague physical complaints.
During her last hospitalization, one year ago for pneumonia, the nephrologist and pulmonologist told Patient H there was not much else that could be done for her. Despite the poor prognosis, her multiple medical conditions stabilized and she completed a rehabilitation program. She enjoys participating in activities and has developed friendships with some other residents. Over the past year, she has been treated for multiple infections, including bronchitis and multiple urinary tract infections.
Patient H's chief complaint is of feeling tired and short of breath at times. She also complains of arthritic pains in her neck and hands. Review of systems is notable for hearing loss, dentures, glasses, and dyspnea, mostly with exertion. She has occasional palpitations of the heart and orthopnea at times. Her bowel movements are regular, and she has not noticed any blood in the stool. She has 1+ chronic edema of the legs, which is about usual for her. She has not had a mammogram for 5 years, and she has not had a dual energy x-ray absorptiometry scan, colonoscopy, or other preventive care recently.
Patient H's record indicates an allergy to sulfa drugs and penicillin. She also has completed advance directives (a do not resuscitate order and a living will). She is taking the following medications:
Amlodipine besylate (Norvasc): 5 mg/day
Calcium carbonate (OsCal) with vitamin D twice daily
Polyethylene glycol powder (Miralax): 17 g in 8 oz liquid daily
Furosemide (Lasix): 40 mg/day
Escitalopram (Lexapro): 20 mg/day
Prednisone: 10 mg/day
Omeprazole (Prilosec): 20 mg/day
Cinacalcet (Sensipar): 30 mg/day
Simvastatin (Zocor): 20 mg at bedtime
Tiotropium oral inhalation (Spiriva): 1 cap per inhalation device daily
Vitamin B12: 1,000 mcg twice daily
Enteric-coated aspirin: 81 g/day
Upon physical examination, Patient H appears well-nourished and groomed. She is mildly short of breath at rest but in no apparent pain or distress. She is 5 feet 6 inches tall and weighs 156 pounds. Her vital signs indicate a blood pressure of 132/84 mm Hg; pulse 72 beats/minute; temperature 97.4 degrees F; respirations 20 breaths/minute; and oxygen saturation 94% on 2 L/minute. Her oropharynx is clear, and her neck is supple. There is no lymphadenopathy. The patient is hard of hearing and wears glasses for distance and reading.
Patient H's heart rate is slightly irregular, with a soft systolic ejection murmur. Evaluation of her lungs indicates diminished breath sounds in the bases with no adventitious sounds. Abdomen palpation finds it to be soft and non-tender, with active bowel sounds and no signs of hepatosplenomegaly. As noted, Patient H has 1+ non-pitting chronic edema and vascular changes to lower extremities. There are no active skin lesions. Neurologic assessment shows no focal deficit. Extremity strength is rated 4 out of 5. A mini-mental status exam is administered, and the patient scores 22/30, indicating mild cognitive impairment.
Blood is drawn and sent to the laboratory for CBC and a basic metabolic panel. The results are:
Leukocytes: 5,700 cells/mcL
RBC: 3.02 million cells/mcL
Hgb: 8.1 g/dL
MCV: 83 fL
MCH: 26.5 Hgb/cell
Platelets: 150,000 cells/mcL
Glucose: 82 mg/dL
Blood urea nitrogen (BUN): 34 mg/dL
Creatinine: 1.4 mg/dL
GFR: 38 mL/minute/1.73 m2
Patient H is in no apparent distress at present, but she appears to have anemia, as evidenced by the low Hgb. She has chronic kidney disease (stage 3), which may be contributing to the anemia. Further laboratory evaluation is necessary to determine the etiology of the anemia and to determine if specialty referral to gastroenterologist or hematologist is necessary. The clinician orders an iron profile, vitamin B12 and folate levels, reticulocyte count, and stool for occult blood. The results of this testing are:
Vitamin B12: 1,996 pg/mL
Folate: 9.9 mcM
Ferritin: 20 ng/mL
Serum iron: 26 mcg/dL
Unsaturated iron binding capacity: 216 mcg/dL
Total iron binding capacity: 242 mcg/dL
Transferrin saturation: 11%
Reticulocyte count: 1%
Stool for occult blood: Negative (three samples)
Vitamin B12 is a water-soluble vitamin that is excreted in urine, so a high level is generally not significant. The folate level is sufficient, while the ferritin level is considered low-to-normal. The iron profile shows a low level of iron in the blood; this may be caused by gastrointestinal bleeding or by inadequate absorption of iron by the body. Patient H has medical conditions that can cause elevated cytokines, which would interfere with iron absorption. If her ferritin level was high, which it is not, it would suggest AI/ACD. Therefore, the patient appears to have anemia secondary to chronic kidney disease.
Prior to initiating treatment with an ESA, the patient is evaluated for a history of cancer, as these agents may cause progression/recurrence of cancer. Before writing the prescription for darbepoetin alfa, the clinician signs the ESA APPRISE Oncology Patient and Healthcare Professional Acknowledgement Form to document discussing the risks associated with darbepoetin alfa with the patient. The lowest dose that will prevent blood transfusion is prescribed.
The multidisciplinary team works with Patient H to develop a treatment plan. It is determined that treating the anemia will improve the patient's quality of life. The patient is prescribed ferrous sulfate 325 mg twice daily. Because vitamin C facilitates iron absorption, the iron can be given with a glass of orange juice or other citrus juice (not grapefruit). Iron must not be given with calcium, milk products, and certain medications as they can interfere with absorption. The patient should be monitored for the development of constipation and the need for stool softeners. In addition, darbepoetin alfa 40 mcg is prescribed, to be administered subcutaneously every week. This requires significant monitoring. Hgb and HCT should be measured on the day patient is to receive the injection, and the drug should be held if the Hgb is greater than 11.5 g/dL. If a current Hgb level is unavailable, the drug should not be given.
Blood pressure should be measured twice daily after treatment with darbepoetin alfa is initiated. Staff must also monitor for symptoms of a deep vein thrombosis and pulmonary embolus (e.g., unilateral edema, cough, and/or hemoptysis). Daily exercise is encouraged to help reduce the risk of a blood clot.
After one month, Patient H has received darbepoetin alfa weekly for 4 weeks. She is also taking the ferrous sulfate and a stool softener. The review of systems is unchanged from the previous evaluation. The physical examination is also unchanged aside from a 1-pound weight loss. No new complaints or problems are reported. A review of the patient's vital signs shows a blood pressure of 130/80 mm Hg; pulse 78 beats/minute; temperature 97.8 degrees F; and oxygen saturation 97 on 2 L/minute. Her Hgb levels over the last month have improved:
Week 1: 8.4 g/dL
Week 2: 9.2 g/dL
Week 3: 9.6 g/dL
Week 4: 10.1 g/dL
No side effects as a result of the darbepoetin alfa are observed. Patient H's blood pressure remains stable, with no signs or symptoms of a blood clot.
The clinician orders the weekly monitoring of Hgb and HCT to continue with the darbepoetin alfa held if the Hgb is greater than 11.5 g/dL. If the medication is held more than once, the clinician will re-evaluate the dosage and frequency. The patient may only need the injection once or twice a month after the anemia is stabilized. The clinician also reduces the patient's vitamin B12 supplement to daily (rather than twice daily) and reduces her prednisone dose to 5 mg/day.
Patient H's initial complaint was of shortness of breath and fatigue. These symptoms may have been related to the anemia or may have been a chronic complaint secondary to her congestive heart failure and COPD. The decreased hematocrit level is likely contributing to the patient's symptomatic heart failure. By exploring her condition further, it was determined that treating the anemia might improve the patient's quality of life and prevent the necessity for more extreme interventions (e.g., blood transfusion). Patient H was informed of the potential side effects of darbepoetin alfa and agreed to take it to prevent transfer to the hospital for blood transfusion.
The patient's condition was monitored closely, with weekly blood draws for Hgb. Her blood pressure remained stable, and no signs of complications were detected. Her shortness of breath and fatigue improved as the treatment progressed and her Hgb level rose above 10 g/dL. This allowed her to be more active and to remain in her home with familiar caregivers.
For patients with terminal or end-stage conditions, treatment of anemia can restore or preserve their quality of life. Treating problems that could potentially cause suffering, while avoiding futile care, is the goal for patients with a life-limiting condition. Anemia affects the quality of life in elders by causing fatigue, poor endurance, and shortness of breath, and alleviating these symptoms can allow for more activity and comfort.
Patient P is a white man, 92 years of age, who resides in an assisted living facility. He uses a motorized scooter for mobility but is able to ambulate short distances with his rolling walker. He requires assistance with medication administration and attends community meals three times a day. His daughter visits once a week and assists with laundry and transports to medical appointments.
Patient P is brought to the primary care clinic by his daughter. She states that he is very fatigued and is not performing his usual daily tasks. He sleeps more than is usual and has to be coaxed to attend the community meals. At times, he has refused to take medications that the staff attempt to administer. The patient minimizes his symptoms saying, "What do you expect? I'm 92 years old." Patient P's medical history is positive for Parkinson's disease, hypertension, COPD, osteoporosis, compression fracture to the lumbosacral spine, and weight loss. He is a widower and reports no tobacco use and rarely drinking beer or wine. His chief presenting complaints are fatigue, shortness of breath, chronic back and leg pain, and poor appetite.
On review of systems, the patient is noted to be hard of hearing and wearing a hearing aid. Vision is adequate with correction. He wears dentures and denies pain or difficulty with mastication. He has difficulty swallowing large pills, and his caregivers crush his medications. He states his appetite is not good; he has lost 15 pounds over the last year. Patient P denies chest pain, but complains of shortness of breath. This occurs when he exerts himself and often when he lays down. He has a regular bowel movement every 1 to 2 days and denies nausea, vomiting, or diarrhea. He has not had dyspepsia but does state he does not seem to be able to eat as much as he used to (early satiety). He complains of nonradiating pain in his lower back. All other review of systems is non-contributory. Patient P has previously been tried on antiparkinsonian medications and osteoporosis medications that were discontinued due to unacceptable side effects. He is currently taking the following medications:
Atenolol (Tenormin): 25 mg twice daily
Vitamin D3: 1,000 units/day
Calcium carbonate: 500 mg three times every day
Vitamin B12: 1,000 mcg/day
Amlodipine (Norvasc): 10 mg/day
Omeprazole: 20 mg/day
Tiotropium oral inhalation (Spiriva): 1 cap per inhalation device daily
Acetaminophen (Tylenol): 650 mg three times daily routinely
Stool softener twice daily
Tramadol (Ultram): 50 mg every 6 hours as needed
Upon physical examination, Patient P appears frail but well groomed; he is in no apparent distress. He is 5 feet 5 inches tall and weighs 134 pounds. His vital signs indicate a blood pressure of 110/64 mm Hg; pulse 82 beats/minute (regular rate and rhythm); temperature 97.8 degrees F; respirations 22 breaths/minute; and oxygen saturation 91% on room air.
As noted, the patient is hard of hearing with hearing aid and wears glasses. There is no evidence of lymphadenopathy or carotid bruit. His oropharynx is clear. His lungs are clear to auscultations, with diminished air flow in lung bases. The abdomen is soft and non-tender, not distended, with bowel sounds active in 4 quadrants. There is no hepatosplenomegaly. Extremities are clear of edema. Vascular changes are noted on both legs, and the toenails are thickened. The patient displays dry, flaky skin of lower extremities. Tenderness is noted over the lumbar spine with palpation. Disuse atrophy is noted to the extremities. Chronic skin lesions are also present, with actinic keratoses on the nose and forehead. Neurologic assessment reveals fine resting tremor of both hands and flat affect. Strength is equal bilaterally with strong hand grasps. Gait and balance are unsteady.
The clinician orders Patient P's medical records and diagnostics from previous care providers. She also requests a CBC with differential, a complete metabolic profile, and thyroid studies. A home health care evaluation is also recommended to determine if rehabilitation services would be appropriate. Patient P's laboratory studies indicate:
Leukocytes: 5,400 cells/mcL
RBC: 2.95 million cells/mcL
Hgb: 8.7 g/dL
MCV: 88 fL
MCH: 29.4 Hgb/cell
Platelets: 289,000 cells/mcL
Glucose: 77 mg/dL
BUN: 20 mg/dL
Sodium: 139 mEq/L
Potassium: 4.5 mEq/L
Chloride: 104 mmol/L
Carbon dioxide: 27 mmol/L
Creatinine: 0.9 mg/dL
Calcium: 8.8 mg/dL
GFR: Greater than 60 mL/minute/1.73 m2
Thyroid-stimulating hormone: 2.88 mIU/L
The low RBC, Hgb, and HCT indicate that the patient has a normocytic, normochromic anemia. However, blood-loss anemia is not ruled out by lack of microcytosis. If the blood loss is recent, changes to the cells may not yet be evident. The RDW-CV is normal, which may indicate a lack of erythropoietic response. Further laboratory evaluation is indicated.
The clinician requests an iron profile, ferritin level, folate level, vitamin B12 level, reticulocyte count, and stool for occult blood. The results of this testing are:
Vitamin B12: 1,006 pg/mL
Folate: 17.2 mcM
Ferritin: 246 ng/mL
Serum iron: 38 mcg/dL
Total iron binding capacity: 197 mcg/dL
Transferrin saturation: 27%
Reticulocyte count: 1.2%
Stool for occult blood: Negative on two samples, mildly positive on third sample
These findings indicate the patient is not deficient in vitamin B12 or folate. The serum iron is low while the ferritin level is high, suggesting adequate iron stores that are not being utilized by the body. This is a diagnostic indicator of anemia of chronic inflammation. The total iron binding capacity is low, showing that the blood's ability to bind transferrin with iron is reduced. Patient P has signs of a "mixed" anemia, the result of both ACI and gastrointestinal blood loss. Elderly patients often have more than one etiology contributing to the anemia, and all the possible causes should be thoroughly evaluated.
One of the stools for occult blood is positive, which may be representative of intermittent gastrointestinal bleeding. The clinician refers the patient to a gastroenterologist for further diagnostic evaluation. An endoscopy and colonoscopy should be performed if the patient and healthcare surrogate are willing. He is also prescribed a 5% lidocaine patch to be applied to his lower back in the morning and to be removed at bedtime.
Patient P visits a gastroenterologist, who performs an endoscopy and a colonoscopy. He is found to have several polyps in the large intestine, which are removed and biopsied during the colonoscopy. He tolerates the procedures well and has no adverse effects. The polyps are found to be benign.
One month later, Patient P returns to the clinic for follow-up. His review of systems is unchanged, although he reports improvement in his lower back pain. His vital signs are all stable. A CBC is completed to monitor the anemia, and the results are:
Leukocytes: 5,600 cells/mcL
RBC: 3.36 million cells/mcL
Hgb: 9.6 g/dL
MCV: 88.0 fL
MCH: 28.7 Hgb/cell
Platelets: 262,000 cells/mcL
Patient P's RBC, Hgb, and HCT have improved slightly. The RDW-CV has also increased, indicating an improved erythropoietic response. The removal of the colon polyps, which may have been causing some intermittent bleeding contributing to the anemia, appears to have improved the patient's condition. Patient P is instructed to return in one month for additional follow-up.
Patient P is a frail, elderly patient with multiple medical problems. From a primary care perspective, it is important to identify any new or existing medical problems that can be treated and improved. Elderly persons often present with multiple vague complaints that do not point to any one disorder. Laboratory evaluation is crucial to narrow down the diagnostic differential.
Because there is an upward trend in the CBC values, the necessity of a blood transfusion is reduced. However, if the anemia worsens, a hematology consult may be necessary. At 92 years of age, the patient is at risk for myelodysplasia, but if present, lower values of leukocytes, RBCs, and platelets would be expected.
While the use of an ESA might result in an improvement in elderly patients, there are multiple side effects and precautions associated with their use. For Patient P, they should be avoided unless truly necessary to prevent the need for transfusions.
Varying degrees of anemia may be present in the elderly patient. It may be common, but it should not be accepted as normal aging. Poorer outcomes are associated with anemic elders, and the mortality rate is increased in these patients. As the geriatric population grows, the incidence of anemia and its complications in this population will become a significant healthcare burden.
Geriatric patients may have psychological, sociological, and physical changes resulting from aging that complicate treatment. Due to multiple possible etiologies of anemia in the elderly, a thorough evaluation is necessary. Anemia may be the first sign of a gastrointestinal malignancy or another underlying condition.
Anemia may be acute or chronic and can be divided into three main categories: blood loss, hemolytic, and suppression. The main types of anemia seen in elders are AI/ACD, anemia of chronic kidney disease, anemia of unknown origin, nutrient-deficiency anemia, hemolytic anemia, and myelodysplasia. The genetic disorders causing anemia are usually not seen in the elderly as they are associated with mortality at a younger age. Aplastic anemia is a rare form of anemia that may be seen in the elderly and can be fatal if left untreated.
Primary care providers should be proficient in the initial work-up of the anemic elder. Often, there are multiple medical comorbidities requiring specialist referral. A good working relationship with gastroenterologists and hematologists is important, and nephrology referral may be indicated for patients with chronic kidney disease. It is up to the primary care clinician to accumulate all pertinent information from specialists and diagnostics and to establish a plan of care that will benefit the patient. Careful oversight will help prevent redundant tests or treatments and help to reduce unnecessary polypharmacy.
The risk/benefit ratio is such that blood transfusion has little place in the management of most chronic anemias. However, in cases of an Hgb level less than 8 g/dL, a blood transfusion may be necessary and can be given while the work-up for anemia is being conducted. Dangers of repeated blood transfusions include iron overload, hemochromatosis, alloimmunization, and other adverse reactions.
Anemia can impair older patients' quality of life by causing fatigue, dyspnea, and other vague but troubling symptoms. Improving anemia will thereby improve the quality of life for these patients, including those who may have life-limiting illnesses.
Anisocytosis: Excessive numbers of cells with varying sizes.
Actinic keratoses: Skin lesions that are rough and dry, considered pre-cancerous. Usually occurring in sun-exposed areas of skin.
Atrophic gastritis: Loss of gastric glandular cells secondary to inflammation of the stomach mucosa.
Atrophic glossitis: Swollen and smooth-appearing tongue.
Cheilitis: Condition of inflammation, redness, ulcerations, or cracks in the lips. Also known as angular stomatitis.
Chelation therapy: Used to remove iron and heavy metals from the body.
Cobalamin: Vitamin B12, a water-soluble vitamin responsible for normal function of the neurologic and hematopoietic systems.
Cytopenia: Deficiency of RBCs, leukocytes, or platelets.
Erythrocyte: Red blood cell.
Erythropoiesis: Production of red blood cells from the bone marrow, usually in the pelvis, vertebrae, sternum, ribs, and proximal femur.
Erythropoietin: Recombinant hematopoietic growth factor produced by the kidneys.
Glomerular filtration rate (GFR): Measure of kidney function and determination of stage of chronic kidney disease. A GFR less than 30 mL/minute/1.73 m2 usually requires evaluation by a nephrologist.
Hemochromatosis: The body's ability to break down and absorb iron is impaired and iron accumulates in the tissues.
Hematopoiesis: The production of blood elements.
Hemolysis: Destruction of blood cells.
Homocysteine: An amino acid in the blood. High levels are associated with cardiovascular disease.
Hypochromic: RBC that is pale due to low amounts of Hgb in the cell.
Inflammatory cytokine: Chemical messenger of the body that produces increased inflammation.
Intermittent claudication: A condition usually secondary to peripheral arterial disease causing cramps, aching, numbness, and fatigue to the calf muscle. Usually relieved by rest.
Leukocytosis: Elevated leukocyte count.
Leukopenia: Deficiency of leukocytes.
Macrocytosis: Condition of having larger than normal RBCs (i.e., MCV greater than 100 fL).
Methylmalonic acid: A substance produced by the body, a byproduct of the breakdown of amino acids. Elevated in vitamin B12 deficiency.
Microcytosis: Condition of having smaller than normal RBCs (i.e., MCV less than 80 fL)
Myelodysplasia: Defective production of blood cells by the bone marrow.
Myelosuppression: Decreased production of blood components by the bone marrow.
Neutropenia: Deficiency of leukocytes.
Normochromic: RBCs that have the normal concentration of Hgb.
Normocytic: Normal sized RBCs.
Orthopnea: Shortness of breath that comes on while lying flat and is prevented or relieved by propping up.
Orthostatic hypotension: Condition whereby blood pressure suddenly falls when a person stands.
Pancytopenia: A reduction below normal range in the number of RBCs, leukocytes, and platelets.
Paresthesia: A transient or chronic numbness and/or tingling of the extremities.
Platelet (thrombocyte): Non-nucleated cellular element in circulating blood active in thrombus formation (clotting).
Poikilocytosis: The presence of abnormally shaped RBCs in the blood.
Polycythemia: Abnormal increase in the circulating RBC mass, indicated by an abnormally high HCT.
Reticulocyte: Immature RBC. Will eventually become a mature RBC in 1 to 4 days.
Thrombocytopenia: Deficiency of platelets.
Thrombocytosis: Abnormal increase in the amount of platelets in the blood.
Transferrin: A glycoprotein that binds iron.
1. Riva E, Tettamanti M, Mosconi P, et al. Association of mild anemia with hospitalization and mortality in the elderly: the Health and Anemia population-based study. Haematologica. 2009;94(1):22-28.
2. Lefebvre P, Duh MS, Buteau S, Bookhart B, Mody SH. Medical costs of untreated anemia in elderly patients with pre-dialysis chronic kidney disease. J Am Soc Nerphrol. 2006;17(12):3497-3502.
3. Bussey LA, Rothfels P. Vitamin B12 deficiency and megaloblastic anemia in elderly female patients in a rural community. Can J Rural Med. 2003;8(3):179-181.
4. Albert CM, Cook NR, Gaziano JM, et al. Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: a randomized trial. JAMA. 2008;299(17):2027-2036.
5. Sharma S, Gage BE, Deych E, Rich MW. Anemia: an independent predictor of death and hospitalizations among elderly patients with atrial fibrillation. Am Heart J. 2009;157(6):1057-1063.
6. Guralnik JM, Eisenstaedt RS, Ferrucci L, Klein HG, Woodman RC. Prevalence of anemia in persons 65 years and older in the United States: evidence for a high rate of unexplained anemia. Blood. 2004;104(8):2263-2268.
7. Salive ME, Cornoni-Huntley J, Guralnik JM, Phillips CL, Wallace RB, Ostfeld AM, et al. Anemia and hemoglobin levels in older persons: relationship with age, gender, and health status. J Am Geriatr Soc. 1992;40:489-496.
8. Skjelbakken T, Langbakk B, Dahl IM, Lochen ML. Haemoglobin and anaemia in a gender perspective: the Tromso Study. Eur J Haematol. 2005;74:381-388.
9. Artz AS, Fergusson D, Drinka PJ, et al. Mechanisms of unexplained anemia in the nursing home. J Am Geriatr Soc. 2004;52(3): 423-427.
10. Steensma DP, Tefferi A. Anemia in the elderly: how should we define it, when does it matter, and what can be done? Mayo Clin Proc. 2007;82(8):958-966.
11. Artz AS. Anemia in Elderly Persons. Available at http://emedicine.medscape.com/article/1339998-overview. Last accessed January 9, 2015.
12. Lipschitz D. Medical and functional consequences of anemia in the elderly. J Am Geriatr Soc. 2003;51(3 Suppl):S10-S13.
13. World Health Organization. Worldwide Prevalence of Anaemia 1993–2005 WHO Global Database on Anaemia. Geneva: World Health Organization; 2008.
14. Price EA, Schrier SL. Anemia in the Older Adult. Available at http://www.uptodate.com/contents/anemia-in-the-older-adult. Last accessed January 9, 2015.
15. Artz A. Racial impact of anemia and mortality in the elderly: abstract and commentary. Clinical Oncology Alert. 2007;23(7):53-54.
16. Aessopos A, Deftereos S, Farmakis D, et al. Cardiovascular adaptation to chronic anemia in the elderly: an echocardiographic study. Clin Invest Med. 2004;27(5):265-273.
17. National Hematologic Diseases Information Service (NHDIS). Anemia of Inflammation and Chronic Disease. Available at http://hematologic.niddk.nih.gov/anemiachronic.aspx. Last accessed January 9, 2015.
18. Schrier SL, Camaschella C. Anemia of Chronic Disease (Anemia of Chronic Inflammation). Available at http://www.uptodate.com/contents/anemia-of-chronic-disease-anemia-of-chronic-inflammation. Last accessed January 9, 2015.
19. Killip S, Bennett JM, Chambers MD. Iron deficiency anemia. Am Fam Physician. 2007;75(5):671-678.
20. Rex DK, Johnson DA, Anderson JC, et al. American College of Gastroenterology guidelines for colorectal cancer screening 2009 [corrected]. Am J Gastroenterol. 2009;104(3):739-750.
21. National Institutes of Health, Office of Dietary Supplements. Dietary Supplement Fact Sheet: Vitamin B12. Available at http://ods.od.nih.gov/factsheets/VitaminB12-HealthProfessional/. Last accessed January 9, 2015.
22. Coté GA, Howden CW. Potential adverse effects of proton pump inhibitors. Curr Gastroenterol Rep. 2008;10(3):208-214.
23. Cotter PE, O'Keeffe ST. Use of proton pump inhibitors is not associated with vitamin B12 deficiency and in older hospital patients: a case control study. Eur Geriatr Med. 2011;2(4):253-255.
24. Valuck RJ, Ruscin JM. A case-control study on adverse effects: H2 blocker or proton pump inhibitor use and risk of vitamin B12 deficiency in older adults. J Clin Epidemiol. 2004;57(4):422-428.
25. Dharmarajan TS, Kanagala MR, Murakonda P, Lebelt AS, Norkus EP. Do acid-lowering agents affect vitamin B12 status in older adults? J Am Med Dir Assoc. 2008;9(3):162-167.
26. Schick P. Megaloblastic Anemia. Available at http://emedicine.medscape.com/article/204066-overview. Last accessed January 9, 2015.
27. Liu KW, Dai LK, Jean W. Metformin-related vitamin B12 deficiency. Age Ageing. 2006;35(2):200-201.
28. de Jager J, Kooy A, Lehert P, et al. Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial. BMJ. 2010;340:c2181.
29. Ting RZ, Szeto CC, Chan MH, Ma KK, Chow KM. Risk factors of vitamin B(12) deficiency in patients receiving metformin.Arch Intern Med. 2006;166(18):1975-1979.
31. National Institutes of Health, Office of Dietary Supplements. Dietary Supplement Fact Sheet: Folate. Available at http://ods.od.nih.gov/factsheets/Folate-HealthProfessional. Last accessed January 9, 2015.
32. National Cancer Institute. Myelodysplastic Syndromes Treatment (PDQ). Available at http://www.cancer.gov/cancertopics/pdq/treatment/myelodysplastic/HealthProfessional. Last accessed January 9, 2015.
33. Clarke R, Halsey J, Lewington S, et al. Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality: meta-analysis of 8 randomized trials involving 37,485 individuals. Ann Intern Med. 2010;170(18):1622-1631.
34. Mason JB. Folate, cancer risk, and the Greek god, Proteus: a tale of two chameleons. Nutr Rev. 2009;67(4):206-212.
35. Sanjoaquin MA, Allen N, Couto E, Roddam AW, Key TJ. Folate intake and colorectal cancer risk: a meta-analytical approach.Int J Cancer. 2005;113(5):825-828.
36. Valent P, Wimazal F, Sperr WR, Horny H-P. Diagnostic criteria and classification of myelodysplastic syndromes. In: Várkonyi J (ed). The Myelodysplastic Syndromes. New York, NY: Springer; 2011: 43-54.
37. Johnson CA, Levey AS, Coresh J, Levin A, Lau J, Eknoyan G. Clinical practice guidelines for chronic kidney disease in adults: part I. Definition, disease stages, evaluation, treatment, and risk factors. Am Fam Physician. 2004;70(5):869-876.
38. National Heart, Lung, and Blood Institute. What is Hemolytic Anemia? Available at http://www.nhlbi.nih.gov/health/health-topics/topics/ha. Last accessed January 9, 2015.
39. National Heart, Lung, and Blood Institute. What is Sickle Cell Anemia? Available at http://www.nhlbi.nih.gov/health/health-topics/topics/sca. Last accessed January 9, 2015.
40. World Health Organization. Sickle Cell Anaemia: Report by the Secretariat. Available at http://apps.who.int/gb/archive/pdf_files/WHA59/A59_9-en.pdf. Last accessed January 9, 2015.
41. National Heart, Lung, and Blood Institute. Who Is at Risk for Sickle Cell Anemia? Available at http://www.nhlbi.nih.gov/health/health-topics/topics/sca/atrisk. Last accessed January 9, 2015.
42. Centers for Disease Control and Prevention. Sickle Cell Disease (SCD): Data and Statistics. Available at http://www.cdc.gov/NCBDDD/sicklecell/data.html. Last accessed January 9, 2015.
43. National Heart, Lung and Blood Institute. What Are Thalassemias? Available at http://www.nhlbi.nih.gov/health/dci/Diseases/Thalassemia/Thalassemia_WhatIs.html. Last accessed January 9, 2015.
45. National Heart, Lung and Blood Institute. What is Aplastic Anemia? Available at http://www.nhlbi.nih.gov/health/health-topics/topics/aplastic/. Last accessed January 9, 2015.
46. National Marrow Donor Program. Severe Aplastic Anemia. Available at http://bethematch.org/for-patients-and-families/learning-about-your-disease/severe-aplastic-anemia. Last accessed January 9, 2015.
48. Taber's Online. Available at http://www.tabers.com/tabersonline. Last accessed January 9, 2015.
49. Lerma E. Anemia of Chronic Disease and Renal Failure: Diagnosis. Available at http://emedicine.medscape.com/article/1389854-overview#aw2aab6b6. Last accessed January 9, 2015.
52. Makipour S, Kanapuru B, Ershler WB. Unexplained anemia in the elderly. Semin Hematol. 2008;45(4):250-254.
53. Schrier SL, Camaschella C. Anemia of Chronic Disease (Anemia of Chronic Inflammation). Available at http://www.uptodate.com/contents/anemia-of-chronic-disease-anemia-of-chronic-inflammation. Last accessed January 9, 2015.
54. National Kidney Foundation. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Available at https://www.kidney.org/sites/default/files/docs/anemiainckd.pdf. Last accessed January 9, 2015.
55. Lexicomp Online. Available at http://online.lexi.com. Last accessed January 9, 2015.
56. Agnihotri P, Telfer M, Butt Z, et al. Chronic anemia and fatigue in elderly patients: results of a randomized, double-blind, placebo-controlled, crossover exploratory study with epoetin alfa. J Am Geratr Soc. 2007;55(10):1557-1565.
57. Paltiel O, Clarfield AM. Anemia in elderly people: risk marker or risk factor? CMAJ. 2009;181(3-4):129-130.
58. Rimon E, Kagansky N, Kagansky M, et al. Are we giving too much iron? Low-dose iron therapy is effective in octogenarians.Am J Med. 2005;118(10):1142-1147.
59. Brooks M. FDA Approves Injectafer for Iron Deficiency Anemia. Available at http://www.medscape.com/viewarticle/808800. Last accessed January 9, 2015.
60. Schrier SL, Auerbach M. Treatment of the Adult with Iron Deficiency Anemia. Available at http://www.uptodate.com/contents/treatment-of-anemia-due-to-iron-deficiency. Last accessed January 9, 2015.
61. Kim YI. Will mandatory folic acid fortification prevent or promote cancer? Am J Clin Nutr. 2004;80(5):1123-1128.
62. Rosenberg M. Overview of the Management of Chronic Kidney Disease in Adults. Available at http://www.uptodate.com/contents/overview-of-the-management-of-chronic-kidney-disease-in-adults. Last accessed January 9, 2015.
63. Rizzo JD, Lichtin AE, Woolf SH, et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol. 2002;20(19):4083-4107.
64. McKinney M, Arcasoy MO. Erythropoietin for oncology supportive care. Exp Cell Res. 2011;317(9):1246-1254.
65. Maakaron JE. Sickle Cell Anemia. Available at http://emedicine.medscape.com/article/205926-overview. Last accessed January 9, 2015.
66. Bisbe E, Castillo J, Sáez M, Santiveri X, Ruíz A, Munoz M. Prevalence of preoperative anemia and hematinic deficiencies in patients scheduled for elective major orthopedic surgery. Transfusion Alter Transfusion Med. 2008;10(4):166-173.
1. Kidney Disease: Improving Global Outcomes Anemia Work Group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl. 2012;2(4):279-335. Summary retrieved from National Guideline Clearinghouse at http://www.guideline.gov/content.aspx?id=38245. Last accessed January 16, 2015.
2. American Dietetic Association. Celiac Disease: Evidence-Based Nutrition Practice Guideline. Chicago, IL: American Dietetic Association; 2009. Summary retrieved from National Guideline Clearinghouse at http://www.guideline.gov/content.aspx?id=14854. Last accessed January 16, 2015.
3. Finnish Medical Society Duodecim. Blood Transfusion: Indications, Administration and Adverse Reactions. Helsinki: John Wiley & Sons; 2011. Summary retrieved from National Guideline Clearinghouse at http://www.guideline.gov/content.aspx?id=34955. Last accessed January 16, 2015.
Mention of commercial products does not indicate endorsement.